On Mar. 10, 2020, Innovation Pharma announced that management was advised that testing of Brilacidin, the Company’s flagship defensin mimetic drug candidate, as a novel experimental treatment against the latest coronavirus, was scheduled to commence at one of the 12 U.S. Regional Biocontainment Labs (RBLs) during the week of March 16, 2020.